Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study
Main finding · Incident T2DResult — go to the resultHazard ratio 2.55 CI 2.23–2.92Authors' conclusion
These findings highlight the need for age-specific combined assessment and management of chronic inflammation and dyslipidemia in primary prevention against T2D, particularly for young adults. The clinical benefit derived from dual-target intervention against dyslipidemia and inflammation will exceed the sum of each part alone in young adults.
Study context
- Population
- Nondiabetic participants of the Kailuan Study3,987 T2D developed
- Participants
- 42,925 participants
- Exposure
- Co-exposure to high CumAIP and high CumCRP vs low CumAIP and low CumCRP
- Outcome
- Incident T2D
- Follow-up
- Median 6.41 years
Methodological detailsreal-world, age-stratified Cox regression
- Real-world
- Age-stratified Cox regression
Main finding
As reported in the abstract
median 6.41 years
Hazard ratio
2.55
CI 2.23–2.92
CumAIP ≥ - 0.0699 and CumCRP ≥ 3 mg/Lvs CumAIP < −0.0699 and CumCRP < 1 mg/L
HR 2.55 (CI 2.23–2.92)
- CumAIP and CumCRP jointly associated with increased diabetes risk
- P for interaction = 0.0126
Observational data: associations, not effects.
Further findings
Co-exposure HR by age
- < 40 years
- 6.26 (3.47-11.28)
- 40-49 years
- 2.26 (1.77-2.89)
- 50-59 years
- 2.51 (2.00-3.16)
- 60-69 years
- 2.48 (1.86-3.30)
- ≥ 70 years
- 2.10 (1.29-3.40)
- Age interaction
- P for interaction = 0.0193
Additive interaction in young adults (< 45 years)
- Relative excess risk due to interaction
- 0.80, 95% CI 0.10-1.50
Original publication
Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study. Cardiovasc Diabetol. Published 15 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →